Global Scleroderma Diagnostics and Therapeutics Market Research Report 2024

Publication ID:

PB505242543

Publication Date:

May 2, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Scleroderma Diagnostics and Therapeutics market was valued at US$ 2229.5 million in 2023 and is anticipated to reach US$ 4121.4 million by 2030, witnessing a CAGR of 9.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Scleroderma Diagnostics and Therapeutics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Scleroderma Diagnostics and Therapeutics.
Report Scope
The Scleroderma Diagnostics and Therapeutics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Scleroderma Diagnostics and Therapeutics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Scleroderma Diagnostics and Therapeutics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim
Bayer AG
Cytori Therapeutics, Inc.
Cumberland Pharmaceuticals Inc
Gilead Sciences, Inc.
Pfizer, Inc.
Sanofi
Corbus Pharmaceutical Holdings, Inc.
F. Hoffmann La Roche Ltd.
Merck KGaA
Segment by Type
Corticosteroids
Immunosuppressive Agents
Endothelin Receptor Agonists
Calcium Channel Blockers
PDE-5 Inhibitors
Chelating Agents
Prostacyclin Analogues
Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
Segment by Application
Skin Biopsy
Imaging Techniques
Blood Tests
Electrocardiogram and Echocardiogram
Pulmonary Function Tests
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Scleroderma Diagnostics and Therapeutics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Scleroderma Diagnostics and Therapeutics Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Corticosteroids
1.2.3 Immunosuppressive Agents
1.2.4 Endothelin Receptor Agonists
1.2.5 Calcium Channel Blockers
1.2.6 PDE-5 Inhibitors
1.2.7 Chelating Agents
1.2.8 Prostacyclin Analogues
1.2.9 Others (H2 Blockers, Proton Pump Inhibitors, ACE Inhibitors etc.)
1.3 Market by Application
1.3.1 Global Scleroderma Diagnostics and Therapeutics Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Skin Biopsy
1.3.3 Imaging Techniques
1.3.4 Blood Tests
1.3.5 Electrocardiogram and Echocardiogram
1.3.6 Pulmonary Function Tests
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Scleroderma Diagnostics and Therapeutics Market Perspective (2019-2030)
2.2 Scleroderma Diagnostics and Therapeutics Growth Trends by Region
2.2.1 Global Scleroderma Diagnostics and Therapeutics Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Scleroderma Diagnostics and Therapeutics Historic Market Size by Region (2019-2024)
2.2.3 Scleroderma Diagnostics and Therapeutics Forecasted Market Size by Region (2025-2030)
2.3 Scleroderma Diagnostics and Therapeutics Market Dynamics
2.3.1 Scleroderma Diagnostics and Therapeutics Industry Trends
2.3.2 Scleroderma Diagnostics and Therapeutics Market Drivers
2.3.3 Scleroderma Diagnostics and Therapeutics Market Challenges
2.3.4 Scleroderma Diagnostics and Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Scleroderma Diagnostics and Therapeutics Players by Revenue
3.1.1 Global Top Scleroderma Diagnostics and Therapeutics Players by Revenue (2019-2024)
3.1.2 Global Scleroderma Diagnostics and Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Scleroderma Diagnostics and Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Scleroderma Diagnostics and Therapeutics Revenue
3.4 Global Scleroderma Diagnostics and Therapeutics Market Concentration Ratio
3.4.1 Global Scleroderma Diagnostics and Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Scleroderma Diagnostics and Therapeutics Revenue in 2023
3.5 Scleroderma Diagnostics and Therapeutics Key Players Head office and Area Served
3.6 Key Players Scleroderma Diagnostics and Therapeutics Product Solution and Service
3.7 Date of Enter into Scleroderma Diagnostics and Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Scleroderma Diagnostics and Therapeutics Breakdown Data by Type
4.1 Global Scleroderma Diagnostics and Therapeutics Historic Market Size by Type (2019-2024)
4.2 Global Scleroderma Diagnostics and Therapeutics Forecasted Market Size by Type (2025-2030)
5 Scleroderma Diagnostics and Therapeutics Breakdown Data by Application
5.1 Global Scleroderma Diagnostics and Therapeutics Historic Market Size by Application (2019-2024)
5.2 Global Scleroderma Diagnostics and Therapeutics Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Scleroderma Diagnostics and Therapeutics Market Size (2019-2030)
6.2 North America Scleroderma Diagnostics and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Scleroderma Diagnostics and Therapeutics Market Size by Country (2019-2024)
6.4 North America Scleroderma Diagnostics and Therapeutics Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Scleroderma Diagnostics and Therapeutics Market Size (2019-2030)
7.2 Europe Scleroderma Diagnostics and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Scleroderma Diagnostics and Therapeutics Market Size by Country (2019-2024)
7.4 Europe Scleroderma Diagnostics and Therapeutics Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Scleroderma Diagnostics and Therapeutics Market Size (2019-2030)
8.2 Asia-Pacific Scleroderma Diagnostics and Therapeutics Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Scleroderma Diagnostics and Therapeutics Market Size by Region (2019-2024)
8.4 Asia-Pacific Scleroderma Diagnostics and Therapeutics Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Scleroderma Diagnostics and Therapeutics Market Size (2019-2030)
9.2 Latin America Scleroderma Diagnostics and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Scleroderma Diagnostics and Therapeutics Market Size by Country (2019-2024)
9.4 Latin America Scleroderma Diagnostics and Therapeutics Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size (2019-2030)
10.2 Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size by Country (2019-2024)
10.4 Middle East & Africa Scleroderma Diagnostics and Therapeutics Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Actelion Pharmaceuticals, Inc.
11.1.1 Actelion Pharmaceuticals, Inc. Company Detail
11.1.2 Actelion Pharmaceuticals, Inc. Business Overview
11.1.3 Actelion Pharmaceuticals, Inc. Scleroderma Diagnostics and Therapeutics Introduction
11.1.4 Actelion Pharmaceuticals, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.1.5 Actelion Pharmaceuticals, Inc. Recent Development
11.2 Boehringer Ingelheim
11.2.1 Boehringer Ingelheim Company Detail
11.2.2 Boehringer Ingelheim Business Overview
11.2.3 Boehringer Ingelheim Scleroderma Diagnostics and Therapeutics Introduction
11.2.4 Boehringer Ingelheim Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.2.5 Boehringer Ingelheim Recent Development
11.3 Bayer AG
11.3.1 Bayer AG Company Detail
11.3.2 Bayer AG Business Overview
11.3.3 Bayer AG Scleroderma Diagnostics and Therapeutics Introduction
11.3.4 Bayer AG Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.3.5 Bayer AG Recent Development
11.4 Cytori Therapeutics, Inc.
11.4.1 Cytori Therapeutics, Inc. Company Detail
11.4.2 Cytori Therapeutics, Inc. Business Overview
11.4.3 Cytori Therapeutics, Inc. Scleroderma Diagnostics and Therapeutics Introduction
11.4.4 Cytori Therapeutics, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.4.5 Cytori Therapeutics, Inc. Recent Development
11.5 Cumberland Pharmaceuticals Inc
11.5.1 Cumberland Pharmaceuticals Inc Company Detail
11.5.2 Cumberland Pharmaceuticals Inc Business Overview
11.5.3 Cumberland Pharmaceuticals Inc Scleroderma Diagnostics and Therapeutics Introduction
11.5.4 Cumberland Pharmaceuticals Inc Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.5.5 Cumberland Pharmaceuticals Inc Recent Development
11.6 Gilead Sciences, Inc.
11.6.1 Gilead Sciences, Inc. Company Detail
11.6.2 Gilead Sciences, Inc. Business Overview
11.6.3 Gilead Sciences, Inc. Scleroderma Diagnostics and Therapeutics Introduction
11.6.4 Gilead Sciences, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.6.5 Gilead Sciences, Inc. Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Detail
11.7.2 Pfizer, Inc. Business Overview
11.7.3 Pfizer, Inc. Scleroderma Diagnostics and Therapeutics Introduction
11.7.4 Pfizer, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.7.5 Pfizer, Inc. Recent Development
11.8 Sanofi
11.8.1 Sanofi Company Detail
11.8.2 Sanofi Business Overview
11.8.3 Sanofi Scleroderma Diagnostics and Therapeutics Introduction
11.8.4 Sanofi Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.8.5 Sanofi Recent Development
11.9 Corbus Pharmaceutical Holdings, Inc.
11.9.1 Corbus Pharmaceutical Holdings, Inc. Company Detail
11.9.2 Corbus Pharmaceutical Holdings, Inc. Business Overview
11.9.3 Corbus Pharmaceutical Holdings, Inc. Scleroderma Diagnostics and Therapeutics Introduction
11.9.4 Corbus Pharmaceutical Holdings, Inc. Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.9.5 Corbus Pharmaceutical Holdings, Inc. Recent Development
11.10 F. Hoffmann La Roche Ltd.
11.10.1 F. Hoffmann La Roche Ltd. Company Detail
11.10.2 F. Hoffmann La Roche Ltd. Business Overview
11.10.3 F. Hoffmann La Roche Ltd. Scleroderma Diagnostics and Therapeutics Introduction
11.10.4 F. Hoffmann La Roche Ltd. Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.10.5 F. Hoffmann La Roche Ltd. Recent Development
11.11 Merck KGaA
11.11.1 Merck KGaA Company Detail
11.11.2 Merck KGaA Business Overview
11.11.3 Merck KGaA Scleroderma Diagnostics and Therapeutics Introduction
11.11.4 Merck KGaA Revenue in Scleroderma Diagnostics and Therapeutics Business (2019-2024)
11.11.5 Merck KGaA Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Actelion Pharmaceuticals, Inc.
Boehringer Ingelheim
Bayer AG
Cytori Therapeutics, Inc.
Cumberland Pharmaceuticals Inc
Gilead Sciences, Inc.
Pfizer, Inc.
Sanofi
Corbus Pharmaceutical Holdings, Inc.
F. Hoffmann La Roche Ltd.
Merck KGaA

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂